GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q1 2014 Financial Results and Host Conference Call on 5 February, 2014

Tickers: GWPH
LONDON, Jan. 29, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2014 its first quarter financial results for the period ending 31 December, 2013. GW will also host a conference call the same day at 1:00 p.m. GMT (8:00 a.m. EST).

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.
About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet syndrome, a severe infantile-onset, genetic, drug-resistant epilepsy syndrome. Our product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia.

CONTACT: Enquiries:

         

         GW Pharmaceuticals plc

         

         Justin Gover, CEO

         +44 1980 557000

         

         Stephen Schultz, VP Investor Relations

         + 1 401 500 6570

         

         FTI Consulting

         

         Ben Atwell / Simon Conway / John Dineen

         (European media enquiries)

         +44 20 7831 3113

         

         Robert Stanislaro (US media enquiries)

         +1 212 850 5657

         

         Trout Group, LLC (US investor relations)

         

         Todd James / Chad Rubin

         +1 646 378 2900

distributed by

This noodl was issued by GW Pharmaceuticals plc and was initially posted at www.gwpharm.com. It was distributed, unedited and unaltered, by noodls on 2014-01-29 08:28:00 CET. The issuer is solely responsible for the accuracy of the information contained therein.